NASDAQ:ALBO - Albireo Pharma Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $72.67
  • Forecasted Upside: 204.55 %
  • Number of Analysts: 3
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 3 Buy Ratings
  • 0 Strong Buy Ratings
$23.86
▲ +1.17 (5.16%)

This chart shows the closing price for ALBO by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Albireo Pharma Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for ALBO and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ALBO

Analyst Price Target is $72.67
▲ +204.55% Upside Potential
This price target is based on 3 analysts offering 12 month price targets for Albireo Pharma in the last 3 months. The average price target is $72.67, with a high forecast of $80.00 and a low forecast of $66.00. The average price target represents a 204.55% upside from the last price of $23.86.

This chart shows the closing price for ALBO for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 3 polled investment analysts is to buy stock in Albireo Pharma. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 8 buy ratings
  • 0 hold ratings
  • 0 sell ratings
2/18/2021
  • 0 strong buy ratings
  • 8 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/19/2021
  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
8/17/2021
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/15/2021
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
2/13/2022
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/14/2022
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/13/2022
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
8/12/2022

Latest Recommendations

  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/17/2022WedbushReiterated RatingBuy$72.00High
5/17/2022Robert W. BairdLower Price Target$72.00 ➝ $66.00High
3/28/2022WedbushInitiated CoverageOutperform$75.00Medium
12/20/2021WedbushReiterated RatingBuy$84.00Medium
11/5/2021HC WainwrightBoost Price TargetBuy$79.00 ➝ $80.00High
10/14/2021Robert W. BairdReiterated RatingBuy$72.00High
9/16/2021WedbushBoost Price TargetOutperform$82.00 ➝ $84.00Low
9/8/2021HC WainwrightReiterated RatingBuy$79.00High
7/22/2021Robert W. BairdBoost Price TargetOutperform$67.00 ➝ $72.00High
7/21/2021WedbushBoost Price TargetOutperform$73.00 ➝ $82.00High
7/21/2021HC WainwrightBoost Price TargetBuy$76.00 ➝ $79.00Low
3/26/2021Jefferies Financial GroupBoost Price TargetPositive ➝ Buy$79.00 ➝ $82.00High
3/1/2021Piper SandlerBoost Price TargetOverweight$68.00 ➝ $81.00Low
3/1/2021Robert W. BairdReiterated RatingBuy$67.00Low
12/18/2020HC WainwrightBoost Price TargetBuy$67.00 ➝ $75.00High
11/19/2020WedbushReiterated RatingBuy$66.00Low
9/18/2020WedbushReiterated RatingBuy$62.00High
9/10/2020CowenBoost Price Target$39.00 ➝ $65.00Medium
9/8/2020Jefferies Financial GroupBoost Price TargetPositive ➝ Buy$50.00 ➝ $79.00High
9/8/2020Needham & Company LLCBoost Price TargetBuy$50.00 ➝ $68.00High
9/8/2020HC WainwrightBoost Price TargetPositive ➝ Buy$50.00 ➝ $67.00High
9/8/2020Piper SandlerBoost Price TargetOverweight$45.00 ➝ $81.00High
8/19/2020HC WainwrightLower Price TargetBuy$64.00 ➝ $50.00High
8/10/2020William BlairReiterated RatingBuyLow
7/30/2020Piper SandlerInitiated CoverageOverweight$45.00High
7/28/2020Needham & Company LLCReiterated RatingBuy$50.00Medium
7/27/2020CowenReiterated RatingOutperform$39.00Medium
7/16/2020HC WainwrightBoost Price TargetBuy$62.00 ➝ $64.00Medium
6/24/2020Robert W. BairdInitiated CoverageOutperform$52.00High
6/17/2020WedbushReiterated RatingOutperformHigh
6/16/2020Needham & Company LLCInitiated CoverageBuy$50.00Medium
6/14/2020HC WainwrightReiterated RatingBuy$62.00Medium
5/11/2020WedbushReiterated RatingBuy$60.00High
5/7/2020Needham & Company LLCInitiated CoverageBuy$50.00High
4/5/2020HC WainwrightReiterated RatingBuy$62.00High
3/5/2020CowenReiterated RatingBuy$39.00Low
3/3/2020HC WainwrightReiterated RatingBuy$62.00High
3/3/2020WedbushLower Price TargetOutperform$69.00 ➝ $60.00High
1/30/2020HC WainwrightReiterated RatingBuy$62.00High
11/6/2019CowenReiterated RatingBuy$39.00Low
11/6/2019WedbushReiterated RatingBuy$69.00Low
8/11/2019HC WainwrightReiterated RatingBuy$62.00Medium
8/9/2019WedbushReiterated RatingOutperform$69.00High
7/15/2019William BlairReiterated RatingBuyLow
7/11/2019WedbushSet Price TargetBuy$69.00Medium
7/10/2019HC WainwrightReiterated RatingBuy$62.00High
5/23/2019WedbushSet Price TargetBuy$69.00Low
5/9/2019William BlairReiterated RatingOutperformHigh
4/17/2019CowenReiterated RatingBuyHigh
3/10/2019WedbushSet Price TargetBuy$69.00High
2/28/2019HC WainwrightInitiated CoverageBuy ➝ Buy$62.00High
1/25/2019WedbushReiterated RatingBuy$69.00Low
11/14/2018CowenReiterated RatingBuyMedium
11/13/2018Needham & Company LLCReiterated RatingBuy$50.00Low
10/17/2018WedbushReiterated RatingBuy$69.00Medium
8/8/2018CowenReiterated RatingBuyHigh
8/7/2018WedbushReiterated RatingOutperform$69.00Low
7/16/2018WedbushReiterated RatingOutperformLow
6/12/2018WedbushReiterated RatingOutperform$69.00Medium
4/20/2018WedbushReiterated RatingOutperform$63.00Low
4/20/2018Jefferies Financial GroupInitiated CoverageBuy$50.00High
3/28/2018WedbushReiterated RatingOutperform$63.00Medium
3/15/2018Needham & Company LLCInitiated CoverageBuy$50.00High
2/2/2018Needham & Company LLCBoost Price TargetBuy$50.00Low
1/19/2018WedbushReiterated RatingBuyLow
1/3/2018WedbushReiterated RatingBuyHigh
11/17/2017CowenReiterated RatingBuyN/A
11/15/2017Roth CapitalInitiated CoverageBuy ➝ Buy$92.00N/A
10/26/2017Needham & Company LLCReiterated RatingBuyN/A
9/11/2017WedbushReiterated RatingOutperform$58.00Low
8/16/2017CowenInitiated CoverageOutperformHigh
(Data available from 8/12/2017 forward)

News Sentiment Rating

0.93 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 2 very positive mentions
  • 7 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
1/14/2022
  • 1 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
2/13/2022
  • 3 very positive mentions
  • 6 positive mentions
  • 2 negative mentions
  • 1 very negative mentions
3/15/2022
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
4/14/2022
  • 1 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/14/2022
  • 6 very positive mentions
  • 4 positive mentions
  • 3 negative mentions
  • 2 very negative mentions
6/13/2022
  • 4 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/13/2022
  • 3 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
8/12/2022

Current Sentiment

  • 3 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Albireo Pharma logo
Albireo Pharma, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of novel bile acid modulators to treat orphan pediatric liver diseases and other liver or gastrointestinal diseases and disorders. The company offers Bylvay for the treatment of progressive familial intrahepatic cholestasis, as well as in Phase III clinical trial for treating biliary atresia, alagille syndrome, and rare and life-threatening disorder to children; and Elobixibat for the treatment of chronic constipation and other functional diseases. It also engages in the developing of A3907, which is in Phase I clinical trial for the treatment of adult liver diseases; and A2342, a preclinical candidate to treat adult viral and liver diseases. The company has a license agreement with EA Pharma Co., Ltd. for the development and commercialization of elobixibat. Albireo Pharma, Inc. is headquartered in Boston, Massachusetts.
Read More

Today's Range

Now: $23.86
Low: $22.65
High: $24.04

50 Day Range

MA: $21.89
Low: $18.54
High: $26.37

52 Week Range

Now: $23.86
Low: $17.81
High: $37.63

Volume

6,373 shs

Average Volume

189,672 shs

Market Capitalization

$461.93 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.89

Frequently Asked Questions

What sell-side analysts currently cover shares of Albireo Pharma?

The following Wall Street analysts have issued reports on Albireo Pharma in the last year: HC Wainwright, Robert W. Baird, StockNews.com, and Wedbush.
View the latest analyst ratings for ALBO.

What is the current price target for Albireo Pharma?

3 Wall Street analysts have set twelve-month price targets for Albireo Pharma in the last year. Their average twelve-month price target is $72.67, suggesting a possible upside of 204.6%. HC Wainwright has the highest price target set, predicting ALBO will reach $80.00 in the next twelve months. Robert W. Baird has the lowest price target set, forecasting a price of $66.00 for Albireo Pharma in the next year.
View the latest price targets for ALBO.

What is the current consensus analyst rating for Albireo Pharma?

Albireo Pharma currently has 3 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe ALBO will outperform the market and that investors should add to their positions of Albireo Pharma.
View the latest ratings for ALBO.

What other companies compete with Albireo Pharma?

How do I contact Albireo Pharma's investor relations team?

Albireo Pharma's physical mailing address is 10 POST OFFICE SQUARE SUITE 502 SOUTH, BOSTON MA, 02109. The biopharmaceutical company's listed phone number is (857) 254-5555 and its investor relations email address is [email protected] The official website for Albireo Pharma is www.albireopharma.com. Learn More about contacing Albireo Pharma investor relations.